From Arnold G., NYS health activist:
"I have just received a copy of Dr. Burzynski's clinical trial results with antineoplastons as presented at the Comprehensive Cancer Conference of April 2003 from Kees Braam.
It is a sad commentary on the FDA's severe restrictions on Dr.Burzynski's dissemination of truthful and accurate results of his clinical trials that he has been forced to take information down from his website and I have to get "bootlegged" information from a citizen of another country that might get out to the American patient-consumer and possibly break the monopoly on information about cancer treatments. If people can hear about what works, they may be unwilling to continue paying high prices for what doesn't work."
This report gives Objective Respose(OR) rates which are a combination of Complete Response (CR) plus Partial Response (PR) so they are not as detailed as prior results.
The comparison statements are relative to the results of May 2002
These are defined below
The below response rates were categorized as defined by the National Cancer Institute definitions as follows:
Complete Response (CR) required complete disappearance of all content-enhanced tumor(s) on imaging studies for 4 weeks or longer.
Partial Response (PR) required more than 50% reduction in the sum of the products of the greatest perpendicular diameters in contrast enhanced tumor(s) for at least 4 weeks.
Stable Disease (SD) required less than 50% change(either greater or smaller) in the sum of the product of the greatest perpendicular diameters of the contrast enhanced tumor(s) for at least 12 weeks.
Progressive Disease (PD) was greater than 50% increase in the sum of the products of the greatest perpendicular diameters of the contrast enhanced tumor(s)compared with the nadir evaluation or appearance of new lesions.
Low Grade Glioma in Children-19 patients
Objective Rsponse (OR) 74%
Stable Disease (SD) 21%
Progressive Disease 5%
A slight improvement moving from Stable disease to Objective Response.
Brain Stem Glioma -18 patients
A slight deterioration moving from Objective response to stable disease.
High Grade Gliomas 62 patients
There was an increase in enrollment, Objective Response Increased and Both Progressive Disease and Stable Disease decreased slightly in this fairly large sample.
Glioblastoma Multiforme-80 patients
Primitive Neuroectodermal Tumor (PNET)-14 patients
Most are diagnosed with medullablastoma a smaller number with pineoblastoma
There was substantial improvement Progressive Disease and Stable Disease decreasing moving to Objective Response
Rhaboid Tumor of the Central Nervous System
Reports of Clinical Trials with antineoplastons from The University of Kurume Medical School in Japan used Antineoplastons A 10 and AS2-1
Preliminary results with adenocarcinoma of the colon with metastises to the liver, in conjunction with chemotherapy, increased over 5 year survival to 91% compared to 39% in the control group treated with chemotherapy alone.
At Kurume University gave AS2-1 to patients with hepatocellular carcinoma and increased time to a recurrence after standard chemotherapy to 16 months, compred to 5 months in the control group receiving chemotherapy alone.
There was a marked reduction in size of metatastic tumors of the head of the pancreas using both chemotherapy and antineoplaston A10 and AS2-1 by IV for 10 days and then maintenance A10 and AS2-1 capsules and intermittent intraarterial treatment. The patient survived for 3 years from initial diagnosis without limiting his usual activities.
Lung Cancer and Breast Cancer
A patient with large cell carcinoma of the lung and another withn carcinoma of the breasts with bilateral lung metasteses were treated with antineoplastons A 10 & AS2-1 in addition to chemotherapy and radiation provided superior results and less toxicity to chemotherapy alone.
|Remember we are NOT Doctors and have NO medical training.|
This site is like an Encyclopedia - there are many pages, many links on many topics.
Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.